Guido Hartmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guido Hartmann has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Christian Klein
Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
3 shared publications Daiju Iwata
3 shared publicationsDavid T Shima
3 shared publicationsEverson Nogoceke
3 shared publicationsGabriella Widmer
3 shared publicationsJörg Moelleken
3 shared publications
Latest Publications
- Open Access
- 30 April 2019
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 11 (5) , e10666
Erratum To: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- 30 April 2019
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 11 (5) , e10666
Open AccessErratum To: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- Open Access
- 22 May 2017
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 9 (7) , 985
Erratum To: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- 22 May 2017
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 9 (7) , 985
Open AccessErratum To: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- Top Cited PapersOpen Access
- 14 October 2016
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 8 (11) , 1265-1288
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A and angiopoietin‐2 (ANG‐2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF‐A. Simultaneous VEGF‐A and ANG‐2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain‐exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF‐A and ANG‐2. RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next‐generation therapy for neovascular indications of the eye. ![][1] The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. EMBO Mol Med (2016) 8: 1265–1288 [1]: /embed/graphic-1.gif
- 14 October 2016
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 8 (11) , 1265-1288
Top Cited PapersOpen AccessTargeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A and angiopoietin‐2 (ANG‐2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF‐A. Simultaneous VEGF‐A and ANG‐2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain‐exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF‐A and ANG‐2. RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next‐generation therapy for neovascular indications of the eye. ![][1] The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. EMBO Mol Med (2016) 8: 1265–1288 [1]: /embed/graphic-1.gif